Epidemiologic Study to Assess the IGRA Positivity in Populations With a High TB Burden

Brief summary (registry, in English)

The purpose of this study is to conduct a multi-country, multi-site, epidemiologic study designed to assess the proportion of interferon gamma release assay (IGRA) positivity, at site level, and to build capacity to conduct a future TB vaccine efficacy study.

What you commit to

• Study type: Observational
• Participants enrolled: 7203
• From 20 Dec 2021 to the primary completion date, 11 Sept 2023
• 36 sites in 14 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 15 years to 34 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (36)

Sites in registry order. Pick your city on the disease page to sort them by distance.